Skip to main navigation Skip to search Skip to main content

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

  • Sonja B Vliek
  • , Iris Noordhoek
  • , Elma Meershoek-Klein Kranenbarg
  • , Annelot G J van Rossum
  • , Vincent O Dezentje
  • , Agnes Jager
  • , J W Esmeralda Hokken
  • , Hein Putter
  • , Annette W G van der Velden
  • , Mathijs P Hendriks
  • , Sandra D Bakker
  • , Yvonne E A van Riet
  • , Vivianne C G Tjan-Heijnen
  • , Johanneke E A Portielje
  • , Judith R Kroep
  • , Johan W R Nortier
  • , Cornelis J H van de Velde
  • , Sabine C Linn*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

PURPOSE: For postmenopausal patients with breast cancer, previous subgroup analyses have shown a modest benefit from adjuvant bisphosphonate treatment. However, the efficacy of oral nitrogen-containing bisphosphonates such as ibandronate is unclear in this setting. TEAM-IIB investigates adjuvant ibandronate in postmenopausal women with estrogen receptor-positive (ER+) breast cancer.

METHODS: TEAM-IIB is a randomized, open-label, multicenter phase III study. Postmenopausal women with stage I-III ER+ breast cancer and an indication for adjuvant endocrine therapy (ET) were randomly assigned 1:1 to 5 years of ET with or without oral ibandronate 50 mg once daily for 3 years. Major ineligibility criteria were bilateral breast cancer, active gastroesophageal problems, and health conditions that might interfere with study treatment. Primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population.

RESULTS: Between February 1, 2007, and May 27, 2014, 1,116 patients were enrolled, 565 to ET with ibandronate (ibandronate arm) and 551 to ET alone (control arm). Median follow-up was 8.5 years. DFS was not significantly different between the ibandronate and control arms (HR 0.97; 95% CI, 0.76 to 1.24; log-rank P = .811). Three years after random assignment, DFS was 94% in the ibandronate arm and 91% in the control arm. Five years after random assignment, this was 89% and 86%, respectively. In the ibandronate arm, 97/565 (17%) of patients stopped ibandronate early because of adverse events. Significantly more patients experienced GI issues, mainly dyspepsia, in the ibandronate arm than in the control arm (89 [16%] and 54 [10%], respectively; P < .003). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.

CONCLUSION: In postmenopausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and should not be recommended as part of standard treatment regimens.

Original languageEnglish
Pages (from-to)2934-2945
Number of pages19
JournalJournal of Clinical Oncology
Volume40
Issue number25
Early online date20 Apr 2022
DOIs
Publication statusPublished - 1 Sept 2022

Keywords

  • Bisphosphonate-related osteonecrosis
  • Zoledronic acid
  • Mechanisms
  • Metastases
  • Clodronate
  • Tamoxifen
  • Diagnosis
  • Jaw

Fingerprint

Dive into the research topics of 'Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial'. Together they form a unique fingerprint.

Cite this